ArticleCell death & disease2026
M2 macrophages promote lymphatic metastasis by regulating PKM2 nuclear translocation in triple-negative breast cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuroimmune Regulation in Posttraumatic Bone Repair: From Inflammatory Transition to Neurovascular Coupling and Functional Recovery.Journal of cellular physiology · 2026Review
- Neuroimmune regulation of post-traumatic bone regeneration: focus on inflammatory switching and functional recovery.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, is characterised by poor prognosis and frequent lymph node metastasis (LNM), a hallmark of disease progression. Crosstalk between TNBC cells and M2-polarized macrophages drives malignant progression, but the specific mechanisms underlying M2 macrophage-mediated LNM in TNBC remain poorly defined. This study revealed that M2 macrophage-derived TGF-β increases glycolysis and lymphatic metastasis in TNBC via a PKM2-centred axis. TGF-β dually regulates PKM2 by transcriptionally upregulating its expression and posttranslational phosphorylation. This dual regulation drives PKM2-mediated metabolic reprogramming to increase tumour glucose uptake while promoting the nuclear translocation of p-PKM2, which transcriptionally activates the lymphatic growth factors VEGFC/D. VEGFC/D subsequently stimulates VEGF-dependent lymphangiogenesis, accelerating metastasis. Pharmacological PKM2 inhibition blocked PKM2 phosphorylation/nuclear translocation and suppressed VEGFC/D expression, thereby attenuating LNM. Clinically, high M2 macrophage infiltration correlated with a shorter disease-free survival and overall survival, paralleling prognostic trends in cohorts stratified by PKM2, VEGFC/D, or lymphatic density levels. Serum analysis in an independent TNBC cohort confirmed elevated TGF-β levels in LNM-positive versus LNM-negative patients. Our findings identify PKM2 as a driver of M2 macrophage-induced VEGFC/D overexpression and lymphatic metastasis, highlighting its therapeutic potential for TNBC patients with high LNM risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.